Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Inventory (2023 - 2025)

Tg Therapeutics has reported Inventory over the past 3 years, most recently at $125.6 million for Q4 2025.

  • Quarterly results put Inventory at $125.6 million for Q4 2025, up 13.7% from a year ago — trailing twelve months through Dec 2025 was $125.6 million (up 13.7% YoY), and the annual figure for FY2025 was $125.6 million, up 13.7%.
  • Inventory for Q4 2025 was $125.6 million at Tg Therapeutics, down from $147.0 million in the prior quarter.
  • Over the last five years, Inventory for TGTX hit a ceiling of $157.8 million in Q1 2025 and a floor of $27.2 million in Q1 2023.
  • Median Inventory over the past 3 years was $83.0 million (2024), compared with a mean of $89.2 million.
  • Biggest five-year swings in Inventory: skyrocketed 185.51% in 2024 and later increased 13.7% in 2025.
  • Tg Therapeutics' Inventory stood at $39.8 million in 2023, then soared by 177.37% to $110.5 million in 2024, then rose by 13.7% to $125.6 million in 2025.
  • The last three reported values for Inventory were $125.6 million (Q4 2025), $147.0 million (Q3 2025), and $155.2 million (Q2 2025) per Business Quant data.